MDM2 and cancer: This MDM2/MDM4 axis, which is often hyperactive in cancers like soft‐tissue sarcomas, glioblastomas, and breast cancer, has become a major target for therapeutic intervention, with strategies focused on nongenotoxic p53 reactivation [116, 117].